AP&T: Assessment of the predictive power of a non-invasive method for long-term prognosis in patients with metabolic-related fatty liver disease

Fatty liver is often accompanied by hepatic stellate cell hyperplasia, glycoprotein, activated collagen and other extracellular matrix components, and excessive deposition in liver tissue, that is, fatty liver fibrosis, which is the early stage and inevitable stage of liver cirrhosis.

.

Further development of fatty liver eventually leads to the development of hepatic fibrosis, and noninvasive assessment of hepatic fibrosis predicts prognosis in nonalcoholic and alcoholic fatty liver disease, but this has not been demonstrated in metabolic (dysfunction)-associated fatty liver disease (MAFLD) confirmed

Fatty liver is often accompanied by hepatic stellate cell hyperplasia, glycoprotein, activated collagen and other extracellular matrix components, and excessive deposition in liver tissue, that is, fatty liver fibrosis, which is the early stage and inevitable stage of liver cirrhosis.

 

A total of 1239 patients with MAFLD (median age 56 years, male 56.
5%, median body mass index 31kg/m ² ) were analyzed in this study
.

The median follow-up was 62 months, during which 73 (5.

²

 

This study demonstrates that baseline liver stiffness measurements, FIB-4, and a non-invasive predictive model of LIVERFASt can predict overall and liver-related mortality and morbidity in patients with MAFLD and can be used as prognostic endpoints in clinical trials
.

This study demonstrates that baseline liver stiffness measurements, FIB-4, and a non-invasive predictive model of LIVERFASt can predict overall and liver-related mortality and morbidity in patients with MAFLD and can be used as prognostic endpoints in clinical trials
.

Original source:

Marie Decraecker.

Long-term prognosis of patients with metabolic (dysfunction)-associated fatty liver disease by non-invasive methods.
Leave a comment here